Microbial Dysbiosis in Common Variable Immune Deficiencies: Evidence, Causes, and Consequences

Trends in Immunology

Volumn 38, Issue 3, 2017, Pages 206-216

  Berbers, Roos Marijn ^a   Nierkens, Stefan ^a   van Laar, Jacob M ^a   Bogaert, Debby ^b,c   Leavis, Helen L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

autoimmune disease; autoinflammation; common variable immunodeficiency; immune dysregulation; microbiome

Indexed keywords

ANTIBIOTIC AGENT; CD123 ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; T LYMPHOCYTE RECEPTOR;

BACTERIAL TRANSLOCATION; CELL LOSS; COMMON VARIABLE IMMUNODEFICIENCY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSBIOSIS; ENDOTOXEMIA; EXHAUSTION; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; INTESTINE EPITHELIUM; INTESTINE FLORA; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; MYELOID DENDRITIC CELL; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; ANIMAL; AUTOIMMUNITY; BIOLOGICAL MODEL; EVIDENCE BASED MEDICINE; HOMEOSTASIS; IMMUNOLOGY; IMMUNOMODULATION; MICROBIOLOGY; MUCOSAL IMMUNITY;

ANIMALS; AUTOIMMUNITY; COMMON VARIABLE IMMUNODEFICIENCY; DYSBIOSIS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOMODULATION; INFLAMMATION; MODELS, IMMUNOLOGICAL;

EID: 85010733371     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.11.008     Document Type: Review

References (79)

1. 1 Cunningham-Rundles, C., How I treat common variable immune deficiency. Blood 116 (2010), 7–15.
2. 2 Conley, M., et al. Diagnostic criteria for primary immunodeficiencies. Clin. Immunol. 93 (1999), 190–197.
3. 3 Ameratunga, R., et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front. Immunol. 5 (2014), 1–9.
4. 4 Salzer, U., et al. Common variable immunodeficiency – an update. Arthritis Res. Ther. 14 (2012), 1–11.
5. 5 Park, J.H., et al. Perspectives on common variable immune deficiency. Ann. N. Y. Acad. Sci. 1246 (2011), 41–49.
6. 6 Maarschalk-Ellerbroek, L.J., et al. The spectrum of disease manifestations in patients with common variable immunodeficiency disorders and partial antibody deficiency in a university hospital. J. Clin. Immunol. 32 (2012), 907–921.
7. 7 Chapel, H., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112 (2008), 277–287.
8. 8 Resnick, E.S., et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119 (2012), 1650–1657.
9. 9 Barbosa, R.R., et al. Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin. Exp. Immunol. 169 (2012), 263–272.
10. 10 Paquin-Proulx, D., et al. IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One, 8, 2013, e75199.
11. 11 Perreau, M., et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J. Exp. Med. 211 (2014), 2033–2045.
12. 12 Jørgensen, S.F., et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 9 (2016), 1455–1465.
13. 13 Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141.
14. 14 Hooper, L.V., Macpherson, A.J., Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10 (2010), 159–169.
15. 15 Kabat, A.M., et al. Modulation of immune development and function by intestinal microbiota. Trends Immunol. 35 (2014), 507–517.
16. 16 Laugerette, F., et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J. Nutr. Biochem. 22 (2011), 53–59.
17. 17 Brenchley, J.M., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12 (2006), 1365–1371.
18. 18 Sandler, N.G., Douek, D.C., Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat. Rev. Microbiol. 10 (2012), 655–666.
19. 19 Xavier, R.J.P.D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
20. 20 Rojo, Ó.P., et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13 (2007), 269–277.
21. 21 Sandler, N.G., et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203 (2011), 780–790.
22. 22 Sandler, N.G., et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology, 141, 2011 1220-1230.e3.
23. 23 Litzman, J., et al. Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. Clin. Exp. Immunol. 170 (2012), 321–332.
24. 24 Wang, J.E., et al. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 20 (2003), 402–414.
25. 25 Yoshimura, a, et al. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163 (1999), 1–5.
26. 26 Scher, J.U., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013 (2013), 1–20.
27. 27 Palm, N.W., et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158 (2014), 1000–1010.
28. 28 Lozupone, C., et al. Diversity, stability and resilience of the human gut microbiota. Nature 489 (2012), 220–230.
29. 29 Nowak, P., et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 29 (2015), 2409–2418.
30. 30 Sjölund, M., et al. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 139 (2003), 483–487.
31. 31 Dethlefsen, L., Relman, D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4554–4561.
32. 32 Jernberg, C., et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 1 (2007), 56–66.
33. 33 Van Zelm, M.C., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354 (2006), 1901–1912.
34. 34 Kuijpers, T.W., et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. 120 (2010), 214–222.
35. +CD4 germinal center Th cells. J. Immunol. 177 (2006), 4927–4932.
36. 36 Li, J., et al. Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. Nat. Commun., 6, 2015, 6804.
37. 37 Li, J., et al. Understanding the genetic and epigenetic basis of common variable immunodeficiency disorder through omics approaches. Biochim. Biophys. Acta 1860 (2016), 2656–2663.
38. 38 Pabst, O., et al. Secretory IgA in the coordination of establishment and maintenance of the microbiota. Trends Immunol. 37 (2016), 287–296.
39. 39 Van de Ven, a.a J.M., et al. Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies. J. Clin. Immunol. 34 (2014), 962–970.
40. 40 Mantis, N.J., et al. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4 (2011), 603–611.
41. 41 Wei, M., et al. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat. Immunol. 12 (2011), 264–270.
42. + T cells regulate immunoglobulin A selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity 41 (2014), 152–165.
43. 43 Suzuki, K., et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 1981–1986.
44. 44 Macpherson, A.J., Uhr, T., Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303 (2004), 1662–1665.
45. 45 Mantis, N.J., et al. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J. Immunol. 169 (2002), 1844–1851.
46. 46 Fransen, F., et al. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. Immunity 43 (2015), 527–540.
47. 47 Peterson, D.a., et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2 (2007), 328–339.
48. 48 Peterson, D.a., et al. Characterizing the interactions between a naturally primed immunoglobulin a and its conserved Bacteroides thetaiotaomicron species-specific epitope in gnotobiotic mice. J. Biol. Chem. 290 (2015), 12630–12649.
49. 49 Boullier, S., et al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J. Immunol. 183 (2009), 5879–5885.
50. 50 Hand, T.W., The role of the microbiota in shaping infectious immunity. Trends Immunol. 37 (2016), 647–658.
51. 51 Giovannetti, a., et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J. Immunol. 178 (2007), 3932–3943.
52. 52 Wang, N., et al. Selective IgA deficiency in autoimmune diseases. Mol. Med. 17 (2011), 1383–1396.
53. 53 Yoshida, M., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20 (2004), 769–783.
54. 54 Maarschalk-Ellerbroek, L.J., et al. Outcome of screening endoscopy in common variable immunodeficiency disorder and X-linked agammaglobulinemia. Endoscopy 45 (2013), 320–323.
55. 55 Jørgensen, S.F., et al. A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency. Am. J. Gastroenterol. 111 (2016), 1467–1475.
56. 56 Ziegler-Heitbrock, L., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116 (2010), e74–e80.
57. + blood monocytes is expanded in sepsis patients. Blood 82 (1993), 3170–3176.
58. + monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 64 (2012), 671–677.
59. + monocytes. Rheumatology (Oxford). 52 (2013), 1009–1017.
60. 60 Scott-Taylor, T.H., et al. Enhanced formation of giant cells in common variable immunodeficiency: Relation to granulomatousdisease. Clin. Immunol. 175 (2016), 1–9.
61. 61 Taraldsrud, E., et al. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9. Clin. Exp. Immunol. 175 (2014), 439–448.
62. 62 Viallard, J-F., et al. Altered dendritic cell distribution in patients with common variable immunodeficiency. Arthritis Res. Ther. 7 (2005), R1052–R1055.
63. 63 Scott-Taylor, T.H., et al. Defective maturation of dendritic cells in common variable immunodeficiency. Clin. Exp. Immunol. 145 (2006), 420–427.
64. 64 Bayry, J., et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104 (2004), 2441–2443.
65. 65 Cunningham-Rundles, C., et al. TLR9 activation is defective in common variable immune deficiency. J. Immunol. 176 (2006), 1978–1987.
66. 66 Yu, J.E., et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J. Allergy Clin. Immunol. 124 (2009), 349–356.
67. 67 Yu, J.E., et al. TLR-mediated B cell defects and IFN-α in common variable immunodeficiency. J. Clin. Immunol. 32 (2012), 50–60.
68. 68 Yazdani, R., et al. Genetic defects and the role of helper T-cells in the pathogenesis of common variable immunodeficiency. Adv. Biomed. Res., 3, 2014, 2.
69. 69 Hel, Z., et al. Altered serum cytokine signature in common variable immunodeficiency. J. Clin. Immunol. 34 (2014), 971–978.
70. 70 Park, J., et al. Interferon signature in the blood in inflammatory common variable immune deficiency. PLoS One, 8, 2013, e74893.
71. 71 Maarschalk-Ellerbroek, L.J., et al. CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters. J. Clin. Immunol. 34 (2014), 642–654.
72. + T cell responses upon Toll-like receptor activation in common variable immunodeficiency. J. Transl. Med., 14, 2016, 138.
73. 73 Genre, J., et al. Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with common variable immunodeficiency: a link to autoimmunity?. Clin. Immunol. 132 (2009), 215–221.
74. + regulatory T cells function in patients with common variable immunodeficiency. Cell. Immunol. 281 (2013), 129–133.
75. 75 Soheili, H., et al. Evaluation of natural regulatory T cells in subjects with selective IgA deficiency: from senior idea to novel opportunities. Int. Arch. Allergy Immunol. 160 (2013), 208–214.
76. 76 Atarashi, K., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–342.
77. 77 Arpaia, N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504 (2013), 451–455.
78. 78 Cunningham-Rundles, C., Autoimmune manifestations in common variable immunodeficiency. J. Clin. Immunol 28:Suppl 1 (2008), S42–S45.
79. 79 Yong, P.F.K., et al. “A Rose Is a Rose Is a Rose,” but CVID Is Not CVID. Common Variable Immune Deficiency (CVID), What Do We Know in 2011?. 2011, Elsevier.